SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jermaine D. Jones, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne M. Manubay, Shanthi Mogali, Verena Metz, Sandra D. Comer, Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users, Addiction Biology, 2014, 19, 4
  2. 2
    Salvatore V. Colucci, Peter J. Perrino, Megan Shram, Cynthia Bartlett, Yi Wang, Stephen C. Harris, Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users, Clinical Drug Investigation, 2014, 34, 6, 421

    CrossRef

  3. 3
    Caroline Victorri-Vigneau, Cedric Collin, Catherine Messina-Gourlot, Christel Raffournier, Michel Mallaret, Jérôme Besse, Marie-Anne Courne, Nathalie Richard, Véronique Sébille, Philippe Arnaud, Designing a tool allowing for a standardized assessment of resistance to drug diversion, Expert Opinion on Drug Delivery, 2014, 11, 7, 995

    CrossRef

  4. 4
    Louis Alexander, Richard O. Mannion, Brianne Weingarten, Richard J. Fanelli, Gary L. Stiles, Development and impact of prescription opioid abuse deterrent formulation technologies, Drug and Alcohol Dependence, 2014, 138, 1

    CrossRef

  5. 5
    Theodore J. Cicero, Matthew S. Ellis, Hilary L. Surratt, Steven P. Kurtz, Factors contributing to the rise of buprenorphine misuse: 2008–2013, Drug and Alcohol Dependence, 2014,

    CrossRef

  6. 6
    Alicia Casati, Daniela Piontek, Tim Pfeiffer-Gerschel, Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment, Substance Abuse Treatment, Prevention, and Policy, 2014, 9, 1, 19

    CrossRef

  7. 7
    Camille Cohier, Lucie Chevillard, Patricia Risède, Olivier Roussel, Bruno Mégarbane, Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats, Toxicology Letters, 2014, 228, 2, 75

    CrossRef

  8. 8
    Corinne Canestrelli, Nicolas Marie, Florence Noble, Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration, The International Journal of Neuropsychopharmacology, 2014, 17, 09, 1367

    CrossRef

  9. 9
    Verena E. Metz, Laura Brandt, Annemarie Unger, Gabriele Fischer, Substance abuse/dependence treatment: A European perspective, Substance Abuse, 2014, 00

    CrossRef

  10. 10
    Jermaine D. Jones, Gabriela Madera, Sandra D. Comer, The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users, Pharmacology Biochemistry and Behavior, 2014, 122, 299

    CrossRef

  11. 11
    Pertti Heikman, Margareeta Häkkinen, Merja Gergov, Ilkka Ojanperä, Urine naloxone concentration at different phases of buprenorphine maintenance treatment, Drug Testing and Analysis, 2014, 6, 3
  12. 12
    N. Lintzeris, S.Y. Leung, A.J. Dunlop, B. Larance, N. White, G.R. Rivas, R.M. Holland, L. Degenhardt, P. Muhleisen, M. Hurley, R. Ali, A randomised controlled trial of sublingual buprenorphine–naloxone film versus tablets in the management of opioid dependence, Drug and Alcohol Dependence, 2013, 131, 1-2, 119

    CrossRef

  13. 13
    Zev Schuman-Olivier, Hilary Connery, Margaret L. Griffin, Steve A. Wyatt, Alan A. Wartenberg, Jacob Borodovsky, John A. Renner, Roger D. Weiss, Clinician beliefs and attitudes about buprenorphine/naloxone diversion, The American Journal on Addictions, 2013, 22, 6
  14. 14
    B. Rolland, A. Muyssen, T. Danel, O. Cottencin, Faut-il retirer la buprénorphine haut-dosage du marché français ?, Revue d'Épidémiologie et de Santé Publique, 2013, 61, 2, 91

    CrossRef

  15. 15
    M.A. Huestis, E.J. Cone, S.O. Pirnay, A. Umbricht, K.L. Preston, Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans, Drug and Alcohol Dependence, 2013, 131, 3, 258

    CrossRef

  16. 16
    Andrew J. Saxon, Yih-Ing Hser, George Woody, Walter Ling, Medication-assisted treatment for opioid addiction: Methadone and buprenorphine, Journal of Food and Drug Analysis, 2013, 21, 4, S69

    CrossRef

  17. 17
    Margareeta Häkkinen, Pertti Heikman, Ilkka Ojanperä, Parenteral buprenorphine–naloxone abuse is a major cause of fatal buprenorphine-related poisoning, Forensic Science International, 2013, 232, 1-3, 11

    CrossRef

  18. 18
    Thomas A. Nguyen, Jennie H. Hahn, Stephen M. Strakowski, Pharmacotherapies for treating opioid use disorder, CNS Spectrums, 2013, 18, 06, 289

    CrossRef

  19. 19
    M.K. Romach, K.A. Schoedel, E.M. Sellers, Update on tamper-resistant drug formulations, Drug and Alcohol Dependence, 2013, 130, 1-3, 13

    CrossRef

  20. 20
    Shanthi Mogali, Sandra D. Comer, Research and Development of Opioid-Related Ligands, 2013,

    CrossRef

  21. 21
    Andrew J. Saxon, Research and Development of Opioid-Related Ligands, 2013,

    CrossRef

  22. 22
    S. Wee, L. F. Vendruscolo, K. K. Misra, J. E. Schlosburg, G. F. Koob, A Combination of Buprenorphine and Naltrexone Blocks Compulsive Cocaine Intake in Rodents Without Producing Dependence, Science Translational Medicine, 2012, 4, 146, 146ra110

    CrossRef

  23. 23
    Leslie Amass, Vilma Pukeleviciene, Emilis Subata, António Rocha Almeida, Maria Chiara Pieri, Pietro D'Egidio, Zdenka Stankova, António Costa, Bobby P. Smyth, Slavko Sakoman, Yan Wei, John Strang, A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals, Addiction, 2012, 107, 1
  24. 24
    Jeanette M. Tetrault, David A. Fiellin, Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals, Drugs, 2012, 72, 2, 217

    CrossRef

  25. 25
    Perrine Roux, Claudia Tindall, Lionel Fugon, Janet Murray, Suzanne K. Vosburg, Phillip Saccone, Maria A. Sullivan, Jeanne M. Manubay, Ziva D. Cooper, Jermaine D. Jones, Richard W. Foltin, Sandra D. Comer, Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health, Addiction, 2012, 107, 3
  26. 26
    Gavin Bart, Maintenance Medication for Opiate Addiction: The Foundation of Recovery, Journal of Addictive Diseases, 2012, 31, 3, 207

    CrossRef

  27. 27
    Sharon Stancliff, Herman Joseph, Chunki Fong, Terry Furst, Sandra D. Comer, Perrine Roux, Opioid Maintenance Treatment as a Harm Reduction Tool for Opioid-Dependent Individuals in New York City: The Need to Expand Access to Buprenorphine/Naloxone in Marginalized Populations, Journal of Addictive Diseases, 2012, 31, 3, 278

    CrossRef

  28. 28
    Briony Larance, Louisa Degenhardt, Nick Lintzeris, James Bell, Adam Winstock, Paul Dietze, Richard Mattick, Robert Ali, Danielle Horyniak, Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing, Drug and Alcohol Dependence, 2011, 118, 2-3, 265

    CrossRef

  29. 29
    Lisa S. Middleton, Paul A. Nuzzo, Michelle R. Lofwall, David E. Moody, Sharon L. Walsh, The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers, Addiction, 2011, 106, 8
  30. 30
    Erratum, Addiction, 2010, 105, 7